Literature DB >> 32014808

Gender differences and long-term clinical outcomes in patients with chronic total occlusions of infrainguinal lower limb arteries treated from retrograde access with peripheral vascular interventions.

Artur Pawlik1, Rafał Januszek2, Zoltan Ruzsa3, Viktor Óriás4, Paweł Kleczyński1, Joanna Wojtasik-Bakalarz1, Saleh Arif1, Andras Nyerges5, Michał Chyrchel1, Agata Stanek6, Dariusz Dudek7, Stanisław Bartuś7.   

Abstract

PURPOSE: We sought to investigate gender-related differences in clinical outcomes after peripheral vascular interventions (PVIs) from retrograde access in patients with chronic total occlusions (CTOs) of the infrainguinal arteries. PATIENTS AND METHODS: A total of 939 consecutive patients undergoing PVI were enrolled in the study. Patients with peripheral artery diseases (PAD) and CTOs were treated with PVI from retrograde access according to the local protocol. The participants were divided according to gender. Retrograde access included distal puncturing to reach the CTO. The mean follow-up lasted 1,144.9 ± 664.3 days. Baseline characteristics, procedural and long-term outcomes were compared according to gender.
RESULTS: Women represented 37.4% of the study population, and more frequently suffered from hypertension (92% vs. 86%, p = 0.001) and diabetes (54% vs. 46%, p = 0.02). Males more often presented with chronic obstructive pulmonary disease (14.8% vs. 6.8%, p = 0.0003), coronary artery disease (45.4% vs. 32.7%, p = 0.0001), smoking (60.4% vs. 45%, p = 0.007) and prior PVI (25% vs. 17%, p = 0.005). The Kaplan-Meier survival curves at 5 years did not reveal gender-related differences in mortality (p = 0.8), whereas men were at a significantly higher risk of re-PVI during the follow-up period (p = 0.047). Male gender was an independent predictor of re-PVI (Hazard ratio: 1.276; 95% confidence interval: 1.015-1.614, p = 0.03).
CONCLUSION: Males are at increased risk of re-PVI compared to females with PAD and CTOs of infrainguinal arteries treated with PVI from retrograde access.
Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Clinical outcomes; Endovascular revascularization; Gender differences; Peripheral artery disease; Retrograde access

Year:  2020        PMID: 32014808     DOI: 10.1016/j.advms.2020.01.004

Source DB:  PubMed          Journal:  Adv Med Sci        ISSN: 1896-1126            Impact factor:   3.287


  5 in total

Review 1.  Sex Differences in Peripheral Artery Disease.

Authors:  Maria Pabon; Susan Cheng; S Elissa Altin; Sanjum S Sethi; Michael D Nelson; Kerrie L Moreau; Naomi Hamburg; Connie N Hess
Journal:  Circ Res       Date:  2022-02-17       Impact factor: 23.213

Review 2.  Pathogenesis and Clinical Significance of In-Stent Restenosis in Patients with Diabetes.

Authors:  Grzegorz K Jakubiak; Natalia Pawlas; Grzegorz Cieślar; Agata Stanek
Journal:  Int J Environ Res Public Health       Date:  2021-11-15       Impact factor: 3.390

3.  Procedural Outcomes in Patients Treated with Percutaneous Coronary Interventions within Chronic Total Occlusions Stratified by Gender.

Authors:  Zbigniew Siudak; Leszek Bryniarski; Krzysztof Piotr Malinowski; Wojciech Wańha; Wojciech Wojakowski; Sławomir Surowiec; Robert Balan; Sławomir Januszek; Artur Pawlik; Natalia Siwiec; Krzysztof Bryniarski; Andrzej Surdacki; Jacek Legutko; Krzysztof Bartuś; Stanisław Bartuś; Rafał Januszek
Journal:  J Clin Med       Date:  2022-03-04       Impact factor: 4.241

4.  Sex differences in arterial identity correlate with neointimal hyperplasia after balloon injury.

Authors:  Mingjie Gao; Xixiang Gao; Ryosuke Taniguchi; Anand Brahmandam; Yutaka Matsubara; Jia Liu; Hao Liu; Weichang Zhang; Alan Dardik
Journal:  Mol Biol Rep       Date:  2022-06-17       Impact factor: 2.742

Review 5.  Pain Management in People with Diabetes-Related Chronic Limb-Threatening Ischemia.

Authors:  Xiaoyan Jiang; Yi Yuan; Yu Ma; Miao Zhong; Chenzhen Du; Johnson Boey; David G Armstrong; Wuquan Deng; Xiaodong Duan
Journal:  J Diabetes Res       Date:  2021-05-08       Impact factor: 4.061

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.